Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
about
Use of human immunoglobulins as an anti-infective treatment: the experience so far and their possible re-emerging role.Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.CD4-immunoglobulin G2 protects Hu-PBL-SCID mice against challenge by primary human immunodeficiency virus type 1 isolates.Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.Interventions aimed at decreasing the risk of mother-to-child transmission of HIV infection.Use of intravenous immunoglobulins for prophylaxis or treatment of infectious diseases.Cross-clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens following priming with gp120 DNA.The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.Human immunodeficiency virus type 1 neutralization measured by flow cytometric quantitation of single-round infection of primary human T cells.Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemicLonger V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies.Pharmacokinetics of hyperimmune anti-human immunodeficiency virus immunoglobulin in persons with AIDS.A critical question for HIV vaccine development: which antibodies to induce?Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.A vaccine for HIV type 1: the antibody perspective.HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Antibody-based therapies as anti-infective agents.Perinatal transmission of HIV and diagnosis of HIV infection in infants: a review.Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.Adaptation of HIV-1 envelope gp120 to humoral immunity at a population levelAntibodies and Antibody Derivatives: New Partners in HIV Eradication Strategies
P2860
Q30145641-F053F633-5872-4D53-8A82-08327585334AQ33647300-D6AC4FAF-D0FD-418B-8CD6-3FB8AD943754Q33783578-B7C77EDC-7628-43A3-9FDB-81D86CCAA832Q33843554-B086098E-ADA5-40C3-8A02-D7A8676201C7Q33906773-2196F628-D5C5-42F5-9E97-A4334EAAB132Q33999369-7320AD54-839F-41B2-962F-9125418F5A81Q34204047-1552152A-609F-4DD1-92A6-71345525E96DQ34303849-E2F5085B-5906-4485-A0E5-AEF3FDB6463AQ34338761-D4E85758-2AA9-4B39-AEFD-DF41294225D0Q35077704-5B161BC0-61B2-43C2-AEB9-71F3B219D6EFQ35077797-CA70B9C7-44FC-4F61-B391-7D10331EE7D4Q35137276-FD73F57C-02A5-4306-83A7-064973F50434Q35783015-81864A2D-A1B3-4034-AC1E-B2007D208986Q35894716-A07F5707-93C5-461C-95E9-8D33122AAF55Q36037760-B8168164-606D-4F92-9779-E3BC3607099FQ37360774-DBDAAA19-41FB-430A-83A0-0D726E57135CQ39216839-F9242105-2A5E-48AC-B0E9-FBD80388FB50Q41737682-E5A1CC24-4016-4861-8394-D04543D99828Q43872744-399F2168-F4F3-481E-93EF-001AAA8183D5Q58038022-01480B0B-6DCB-42C1-B395-01F860A4836DQ58572618-65324825-1D5E-48BD-BF06-BA6FBECDBAC0
P2860
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh-hant
name
Safety and pharmacokinetics of ...... 5 Pharmacokinetic Study Group.
@en
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus
@nl
type
label
Safety and pharmacokinetics of ...... 5 Pharmacokinetic Study Group.
@en
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus
@nl
prefLabel
Safety and pharmacokinetics of ...... 5 Pharmacokinetic Study Group.
@en
Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus
@nl
P2093
P356
P1476
Safety and pharmacokinetics of ...... 5 Pharmacokinetic Study Group.
@en
P2093
Cummins LM
Fletcher CV
Lambert JS
Mathieson BJ
Meyer WA 3rd
Mofenson LM
P304
P356
10.1093/INFDIS/175.2.283
P407
P577
1997-02-01T00:00:00Z